Revista de neurologia · 2010
[Other non-motor disorders in Parkinson's disease].
Аннотация на английскомСтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Marco-Llorente J, Rojo-Martínez E
Аннотация
INTRODUCTION: In addition to the classic triad (tremor, rigidity and akinesia), Parkinson's disease (PD) is also accompanied by several non-motor disorders.
AIM: To carry out an updated review of these non-motor symptoms in terms of their pathophysiology, epidemiology, clinical features and treatment.
DEVELOPMENT: Autonomic disorders such as seborrhoeic dermatitis and disorders involving sweating, fatigue, weight loss or respiratory problems (dyspnea, inspiratory stridor) are highly prevalent and very disabling symptoms. In addition, they may be the main problem in a particular phase of PD (fatigue, stridor) and condition the quality of life of patients with Parkinson. They are often neglected and remain undetected. Although they may respond to dopaminergic agents, they usually require a different therapeutic approach. Studies are needed to evaluate new therapeutic perspectives that act against the pathophysiological mechanisms of these disorders.
CONCLUSIONS: PD affects systems other than the dopaminergic nigrostriatal. A better understanding of this pathology will make it possible to approach and optimise the treatment of the conditioning symptoms, thereby enhancing the welfare of patients with PD.
AIM: To carry out an updated review of these non-motor symptoms in terms of their pathophysiology, epidemiology, clinical features and treatment.
DEVELOPMENT: Autonomic disorders such as seborrhoeic dermatitis and disorders involving sweating, fatigue, weight loss or respiratory problems (dyspnea, inspiratory stridor) are highly prevalent and very disabling symptoms. In addition, they may be the main problem in a particular phase of PD (fatigue, stridor) and condition the quality of life of patients with Parkinson. They are often neglected and remain undetected. Although they may respond to dopaminergic agents, they usually require a different therapeutic approach. Studies are needed to evaluate new therapeutic perspectives that act against the pathophysiological mechanisms of these disorders.
CONCLUSIONS: PD affects systems other than the dopaminergic nigrostriatal. A better understanding of this pathology will make it possible to approach and optimise the treatment of the conditioning symptoms, thereby enhancing the welfare of patients with PD.